Literature DB >> 11407654

Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

G Grugni1, G Guzzaloni, F Morabito.   

Abstract

The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7-38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9-42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2-14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 microg/kg, iv) or GHRH (1 microg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4+/-2.0; AUC: 588+/-113; nAUC: 483+/-108) and GHRH+PD (GHp: 7.3+/-1.8; AUC: 486+/-122; nAUC: 371+/-250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7+/-3.2, p<0.003; AUC: 1833+/-305, p<0.005; nAUC: 1640+/-263, p<0.0001. GHRH+PD: GHp: 15.1+/-2.4, p<0.009; AUC: 1249+/-248, p<0.003; nAUC: 918+/-230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1+/-3.1, p<0.0001; AUC: 2792+/-158, p<0.0001; nAUC: 2705+/-165, p<0.00005. GHRH+PD: GHp: 27.5+/-3.7, p<0.0001; AUC: 1873+/-251, p<0.0001; nAUC: 1692+/-219, p<0.0005). Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD. Interestingly, low IGF-I values were present in all PWS subjects. Furthermore, no patient with PWS showed normal GH response to the previously performed GH stimulation tests. As already reported, GH release after GHRP-6 or GHRH+PD was significantly lower in OB than in SN subjects. In conclusion, our data indicate that: 1) GH response to GHRP-6 is clearly impaired in PWS; 2) the blunted GH responses to the provocative stimuli in PWS are not an artifact of obesity; 3) short stature in PWS is caused by a complex dysfunction of the hypothalamo-pituitary structures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407654     DOI: 10.1007/BF03343871

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  47 in total

Review 1.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

2.  GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Authors:  A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

3.  Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.

Authors:  M Angulo; M Castro-Magana; B Mazur; J A Canas; P M Vitollo; M Sarrantonio
Journal:  J Pediatr Endocrinol Metab       Date:  1996 May-Jun       Impact factor: 1.634

Review 4.  Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.

Authors:  M Pombo; A Leal-Cerro; J Barreiro; A Peñalva; R Peino; F Mallo; C Dieguez; F F Casanueva
Journal:  J Pediatr Endocrinol Metab       Date:  1996-06       Impact factor: 1.634

5.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

Review 6.  Prader-Willi syndrome and the hypothalamus.

Authors:  D F Swaab
Journal:  Acta Paediatr Suppl       Date:  1997-11

7.  Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.

Authors:  M Cappa; A Grossi; P Borrelli; E Ghigo; J Bellone; S Benedetti; D Carta; S Loche
Journal:  Horm Res       Date:  1993

8.  Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep.

Authors:  V Guillaume; E Magnan; M Cataldi; A Dutour; N Sauze; M Renard; H Razafindraibe; B Conte-Devolx; R Deghenghi; V Lenaerts
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

9.  Prader-Willi syndrome: consensus diagnostic criteria.

Authors:  V A Holm; S B Cassidy; M G Butler; J M Hanchett; L R Greenswag; B Y Whitman; F Greenberg
Journal:  Pediatrics       Date:  1993-02       Impact factor: 7.124

10.  Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.

Authors:  F Cordido; A Peñalva; R Peino; F F Casanueva; C Dieguez
Journal:  Metabolism       Date:  1995-06       Impact factor: 8.694

View more
  6 in total

Review 1.  Growth hormone therapy in the Prader-Willi syndrome.

Authors:  W F Paterson; M D C Donaldson
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

2.  Global deficits in development, function, and gene expression in the endocrine pancreas in a deletion mouse model of Prader-Willi syndrome.

Authors:  Mihaela Stefan; Rebecca A Simmons; Suzanne Bertera; Massimo Trucco; Farzad Esni; Peter Drain; Robert D Nicholls
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-02-22       Impact factor: 4.310

3.  Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes.

Authors:  G Grugni; D Giardino; A Crinò; F Malvestiti; L Ballarati; G Di Giorgio; P Marzullo
Journal:  J Endocrinol Invest       Date:  2010-07-22       Impact factor: 4.256

Review 4.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

Review 5.  Apo-Ghrelin Receptor (apo-GHSR1a) Regulates Dopamine Signaling in the Brain.

Authors:  Andras Kern; Cristina Grande; Roy G Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2014-08-18       Impact factor: 5.555

Review 6.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.